Loading
A phase 2 trial of Decitabine in acute myeloid leukaemia, run by Bio-Path Holdings, Inc., now recruiting.
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML is a phase 2 interventional study registered as NCT02781883 by Bio-Path Holdings, Inc., with 108 participants planned, started 2016-05 and due to reach its primary completion in 2027-12. Interventions recorded: BP1001 in combination with Ventoclax plus decitabine and BP1001 plus decitabine.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Decitabine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.